Finance

Lists
ICY:FRA
Incyte Corp
€107,75
-0,83%
(-0,90) 1D
30 Sep., 08:00:43 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ICY...
Open
€107,75
High
€107,75
Low
€107,75
Mkt. cap
24,97 mjd
Avg. vol.
25,00
Volume
0,00
52-wk high
€115,40
52-wk low
€70,22
No. of employees
3 k
Open
€107,75
High
€107,75
Low
€107,75
Mkt. cap
24,97 mjd
Avg. vol.
25,00
Volume
0,00
52-wk high
€115,40
52-wk low
€70,22
No. of employees
3 k
News stories
From web sources and news partners
Profile
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia. Incyte Corporation currently develops and manufactures prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity. Wikipedia
About Incyte Corp
CEO-
Employees2,84 k
Founded2002
HeadquartersWilmington, Delaware, Verenigde State van Amerika
Sector-
Websiteincyte.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
1,37 mjd
1,51 mjd
1,27 mjd
1,67 mjd
Cost of goods sold
605,58 m
732,55 m
620,43 m
621,91 m
Cost of revenue
605,58 m
732,55 m
620,43 m
621,91 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
328,29 m
388,96 m
327,06 m
350,72 m
Operating expense
328,29 m
388,96 m
327,06 m
350,72 m
Total operating expenses
933,87 m
1,12 mjd
947,49 m
972,63 m
Operating income
432,11 m
385,32 m
325,19 m
701,41 m
Other non operating income
3,25 m
4,22 m
1,75 m
5,26 m
EBT including unusual items
482,31 m
389,94 m
343,60 m
751,51 m
EBT excluding unusual items
461,55 m
419,71 m
360,06 m
744,21 m
Income tax expense
58,14 m
90,66 m
40,27 m
165,91 m
Effective tax rate
12,05%
23,25%
11,72%
22,08%
Other operating expenses
-
-
-
-
Net income
424,17 m
299,28 m
303,33 m
585,60 m
Net profit margin
31,05%
19,86%
23,83%
34,98%
Earnings per share
2,26
1,80
1,81
3,09
Interest and investment income
26,78 m
30,75 m
33,69 m
38,12 m
Interest expense
-592,00 k
-582,00 k
-569,00 k
-582,00 k
Net interest expenses
26,19 m
30,17 m
33,12 m
37,54 m
Depreciation and amortization charges
-
-
-
-
EBITDA
456,13 m
409,30 m
348,99 m
727,89 m
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google-programme